NCT05384756View on ClinicalTrials.gov

TMLI and Alemtuzumab for Treatment of Sickle Cell Disease

PHASE1RecruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

July 13, 2022

Primary Completion Date

December 1, 2026

Study Completion Date

December 1, 2026

Conditions
Sickle Cell Disease
Interventions
DRUG

Alemtuzumab

Given IV

PROCEDURE

Hematopoietic Cell Transplantation

Undergo HCT

RADIATION

Intensity-Modulated Radiation Therapy

Undergo TMLI

DRUG

Sirolimus

Medication to prevent the development of graft-versus-host disease (GVHD)

Trial Locations (1)

91010

RECRUITING

City of Hope Medical Center, Duarte

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER